Rapidly progressive dementia and severe awake bruxism resistance to treatment: An unresolved challenge to treatment
Advances in Pharmacology and Therapeutics Journal · 2022
DOI: 10.18502/aptj.v1i2.8669 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Pharmacology and Therapeutics Journal, 2022. Verfasst von Reza Bidaki und 3 weiteren Autor:innen.
Themen: Demenz
Abstract (Originalsprache)
Background
Bruxism is a chief complaint in some patients with dementia, but there is no clear guideline for its management.Here, we presented a case with awake bruxism. Case presentation: This case report study described an 88-year-old woman with severe rapidly progressive dementia (RPD) and awake bruxism, which was improved with discontinuation of sertraline, quetiapine, gabapentin, and resumption of trazodone.
Conclusion
In this case study, despite taking drugs from different classifications for bruxism treatment, no improvement was seen. Bruxism is an important and challenging condition for physicians and caregivers in dementia patients. Although bruxism needs serious treatment, there is no suitable and well-defined treatment for this disorder. Further studies are needed to suggest an efficient drug for the management of bruxism.
Zitieren
APA
Bidaki, R., Alizadeh, Z., Sadeghi, M., & Zare, A. (2022). Rapidly progressive dementia and severe awake bruxism resistance to treatment: An unresolved challenge to treatment. Advances in Pharmacology and Therapeutics Journal. https://doi.org/10.18502/aptj.v1i2.8669
Vancouver
Bidaki R, Alizadeh Z, Sadeghi M, Zare A. Rapidly progressive dementia and severe awake bruxism resistance to treatment: An unresolved challenge to treatment. Advances in Pharmacology and Therapeutics Journal. 2022. doi:10.18502/aptj.v1i2.8669
BibTeX
@article{Bidaki2022,
author = {Bidaki, Reza and Alizadeh, Zahra and Sadeghi, Milad and Zare, Ali},
title = {Rapidly progressive dementia and severe awake bruxism resistance to treatment: An unresolved challenge to treatment},
journal = {Advances in Pharmacology and Therapeutics Journal},
year = {2022},
doi = {10.18502/aptj.v1i2.8669}
}
EUVIMED